Highlights

  • Telix Pharmaceuticals updates FY25 guidance.
  • Alterity Therapeutics has recently raised AUD 0M through placement for ATH434 development.
  • Argenica Therapeutics has reported FY25 revenue of AUD 73M.

The S&P/ASX 200 Health Care (XHJ) sector tracks Australia’s listed healthcare companies and serves as a key industry benchmark. As of 15 October 2025, the index (XHJ) rose 2.07% to 39,154.80 points from its last close of 38,360.60. Three ASX-listed healthcare companies record notable gains today.

Name

Ticker

CMP (in AUD)

% change as on 15/10/25

Telix Pharmaceuticals Limited

(ASX:TLX)

16.58

15.46%

Alterity Therapeutics Limited

(ASX:ATH)

0.012

13.64%

Argenica Therapeutics Limited

(ASX:AGN)

0.292

21.88%

Telix Pharmaceuticals

Telix Pharmaceuticals Limited (ASX:TLX), an Australian biopharmaceutical company has recently (14 October) reported unaudited group revenue of approximately USD 206M for Q3 2025, up 53% YoY. The company raised its FY 2025 revenue guidance to USD 800–820M. Gozellix® received full reimbursement from the U.S. Centers for Medicare and Medicaid Services (CMS), and Illuccix® is now approved in 19 European markets and the UK, with commercial launches underway in multiple countries. Enrollment continues in Phase 3 trials, including ProstACT® Global and the BiPASS™ study, while pivotal trials for TLX250 and TLX101 have commenced. Telix’s manufacturing facilities in North Melbourne (Australia) and Yokohama (Japan) are preparing for operational readiness. The company completed its final royalty payment related to the acquisition of Advanced Nuclear Medicine Ingredients (ANMI).

Alterity Therapeutics

Alterity Therapeutics Limited (ASX:ATH), an Australian biotech company developing has raised AUD 20.0 m through a placement of shares to Australian and international professional investors. The placement was carried out at AUD 0.012 per share, representing a 7–8% discount to recent prices, with no options issued. Funds will be used to support CMC activities, non-clinical studies, and clinical and regulatory work for ATH434 in Multiple System Atrophy (MSA). The company intends to engage with the FDA on the future development of ATH434.

Argenica Therapeutics

Argenica Therapeutics Limited (ASX:AGN), announced today that ARG-007 treated patients showed a positive trend over placebo in exploratory functional endpoints, including cognition, daily activity independence, and quality of life across all subgroups. Functional outcomes, rather than infarct volume, will serve as the primary endpoint in any Phase 3 trial, aligning with regulatory expectations. Building on these results and signals in slow collateral patients, Argenica plans a targeted Phase 2b in consultation with its global stroke advisory group and potential pharmaceutical partners.

Recently, the company reported FY25 revenue of AUD 3.73M, up 34% from AUD 2.79M in FY24, mainly from R&D tax incentives, grants, and interest income. In the same period, net loss increased 31% to AUD 7.17M from AUD 5.48M in FY24. R&D expenses were AUD 8.13M in FY25, compared to AUD 6.02M in FY24, including Phase 2 trials of ARG-007. Net operating cash outflow was AUD 5.70M in FY25, compared to AUD 5.06M in FY24, with financing inflows of AUD 0.35M, down from AUD 11.63M in FY24.